Short answer
Stryker Corporation (SYK) filed its Q3 2025 10-Q quarterly report on Oct 31, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $6.1B (up 10.2% year over year) with net income of $859M.
Q3 2025 key financials · XBRL
- Revenue
- $6.1B
- +10.2% YoY · +0.6% QoQ
- Net income
- $859M
- +3.0% YoY · −2.8% QoQ
- Operating margin
- 18.7%
- Gross margin
- 63.6%
- EPS (diluted)
- $2.22
- +2.8% YoY · −3.1% QoQ
Source: XBRL data from the Stryker Corporation (SYK) Q3 2025 10-Q on SEC EDGAR. USD.
Stryker Corporation Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $6.06B Q3 2025, up 10.3% vs $5.49B Q3 2024; nine months $17.95B, up 11.1% vs $16.16B prior year
- Operating margin 18.7% Q3 2025 vs 19.7% YoY; nine months margin 17.2% vs 19.2% YoY - adjusted margins improved to 25.6% Q3 and 24.7% YTD
- Best segment: MedSurg & Neurotechnology sales +14.4% Q3 ($3.80B) vs $3.32B prior year; worst performer Orthopaedics +3.9% Q3
- Cash from operations $2.90B YTD 2025 vs $2.31B prior year; investing cash outflow increased to $4.56B driven by $4.81B acquisition of Inari
- Management notes tariffs may increase costs and impact demand; maintains positive outlook with sales growth and operational discipline
Risk Factors
- No material changes to risk factors from 2024 10-K for fiscal 2025 10-Q
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Stryker Corporation quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.